Contact
searchSearch
HMP Global
Login

Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer
Specialty Channel
News
First-Line Zipalertinib Plus Chemotherapy Significantly Improves Progression-Free Survival in EGFR Exon 20-Mutated Non-Small Cell Lung Cancer
09/24/2026
Emily Estrada
Results from the phase 3 REZILIENT 3 trial showed that adding zipalertinib to platinum-pemetrexed chemotherapy significantly improved progression-free survival and response in patients with previously untreated EGFR exon 20 insertion-mutated...
Results from the phase 3 REZILIENT 3 trial showed that adding zipalertinib to platinum-pemetrexed chemotherapy significantly improved progression-free survival and response in patients with previously untreated EGFR exon 20 insertion-mutated...
Results from the phase 3...
09/24/2026
Oncology
News
Amivantamab Plus Chemotherapy Extends Median OS in Final PAPILLON Analysis of EGFR Exon 20-Mutant Non-Small Cell Lung Cancer
09/24/2026
Emily Estrada
Final results from the phase 3 PAPILLON trial showed numerically prolonged overall survival with first-line amivantamab plus chemotherapy in patients with EGFR exon 20 insertion-mutated non-small cell lung cancer, despite substantial...
Final results from the phase 3 PAPILLON trial showed numerically prolonged overall survival with first-line amivantamab plus chemotherapy in patients with EGFR exon 20 insertion-mutated non-small cell lung cancer, despite substantial...
Final results from the phase 3...
09/24/2026
Oncology
News
Chemotherapy-Free Durvalumab Plus Radiation Meets PFS End Point in Locally Advanced Non-Small Cell Lung Cancer
08/19/2026
Emily Estrada
Results from the phase 2 DART trial showed that concurrent and consolidative durvalumab plus definitive thoracic radiation met the prespecified 2-year progression-free survival benchmark in elderly and frail patients with locally advanced...
Results from the phase 2 DART trial showed that concurrent and consolidative durvalumab plus definitive thoracic radiation met the prespecified 2-year progression-free survival benchmark in elderly and frail patients with locally advanced...
Results from the phase 2 DART...
08/19/2026
Oncology
News
Ociperlimab Plus Tislelizumab Fails to Improve Survival Over Pembrolizumab in PD-L1-High Advanced Non-Small Cell Lung Cancer
08/11/2026
Emily Estrada
Ociperlimab plus tislelizumab failed to improve overall survival compared with pembrolizumab as first-line treatment for patients with stage III/IV non-small cell lung cancer and PD-L1 expression of ≥50%, leading to the phase 3 AdvanTIG-302...
Ociperlimab plus tislelizumab failed to improve overall survival compared with pembrolizumab as first-line treatment for patients with stage III/IV non-small cell lung cancer and PD-L1 expression of ≥50%, leading to the phase 3 AdvanTIG-302...
Ociperlimab plus tislelizumab...
08/11/2026
Oncology
News
Adjuvant Ensartinib Demonstrates Significant Disease-Free Survival Benefit in ALK-Positive Non-Small Cell Lung Cancer
07/09/2026
Stephanie Holland
Results from the phase 3 ELEVATE trial demonstrated that adjuvant ensartinib significantly improved disease-free survival compared with placebo in patients with completely resected ALK-positive non-small cell lung cancer, supporting its use...
Results from the phase 3 ELEVATE trial demonstrated that adjuvant ensartinib significantly improved disease-free survival compared with placebo in patients with completely resected ALK-positive non-small cell lung cancer, supporting its use...
Results from the phase 3 ELEVATE...
07/09/2026
Oncology
News
Osimertinib Plus Selumetinib Shows Limited Activity Following First-Line Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer
06/26/2026
Emily Estrada
Results from a phase 2 module of the ORCHARD study demonstrated that osimertinib plus selumetinib showed limited efficacy in patients with EGFR-mutated advanced non-small cell lung cancer harboring acquired BRAF alterations following disease...
Results from a phase 2 module of the ORCHARD study demonstrated that osimertinib plus selumetinib showed limited efficacy in patients with EGFR-mutated advanced non-small cell lung cancer harboring acquired BRAF alterations following disease...
Results from a phase 2 module of...
06/26/2026
Oncology
News
Benmelstobart Plus Anlotinib as Potential New First-Line Option in Advanced NSCLC
05/29/2026
Emily Estrada
Benmelstobart plus chemotherapy followed by maintenance benmelstobart and anlotinib significantly improved progression-free survival compared with a tislelizumab-based regimen in first-line EGFR/ALK/ROS1-wild type advanced non-squamous NSCLC.
Benmelstobart plus chemotherapy followed by maintenance benmelstobart and anlotinib significantly improved progression-free survival compared with a tislelizumab-based regimen in first-line EGFR/ALK/ROS1-wild type advanced non-squamous NSCLC.
Benmelstobart plus chemotherapy...
05/29/2026
Oncology
News
Sunvozertinib Significantly Improves PFS in EGFR-Mutated Non-Small Cell Lung Cancer
05/29/2026
Stephanie Holland
Results from the phase 3 WU-KONG28 trial demonstrated that sunvozertinib significantly improved PFS in previously untreated patients with advanced EGFR-mutated non-small cell lung cancer.
Results from the phase 3 WU-KONG28 trial demonstrated that sunvozertinib significantly improved PFS in previously untreated patients with advanced EGFR-mutated non-small cell lung cancer.
Results from the phase 3...
05/29/2026
Oncology
News
Lorlatinib Maintains Long-Term Benefit in Advanced ALK-Positive Non-Small Cell Lung Cancer
05/27/2026
Emily Estrada
Updated results from the phase 3 CROWN study demonstrate that lorlatinib sustains long-term benefit in treatment-naïve patients with advanced ALK-positive non-small cell lung cancer.
Updated results from the phase 3 CROWN study demonstrate that lorlatinib sustains long-term benefit in treatment-naïve patients with advanced ALK-positive non-small cell lung cancer.
Updated results from the phase 3...
05/27/2026
Oncology
News
Neoadjuvant Lorlatinib Produces Durable Early Outcomes in ALK-Positive NSCLC
05/27/2026
Emily Estrada
Results from a multicenter phase 2 study demonstrated that neoadjuvant lorlatinib induced high pathological response and enabled substantial conversion to surgery in advanced ALK-positive non-small cell lung cancer.
Results from a multicenter phase 2 study demonstrated that neoadjuvant lorlatinib induced high pathological response and enabled substantial conversion to surgery in advanced ALK-positive non-small cell lung cancer.
Results from a multicenter phase...
05/27/2026
Oncology
FDA Approval
FDA Approves Zongertinib for HER2-Mutated Metastatic NSCLC
02/26/2026
Emily Estrada
Based on results from the Beamion LUNG-1 trial, the FDA has approved zongertinib for patients with HER2-mutated unresectable or metastatic non-squamous non-small cell lung cancer.
Based on results from the Beamion LUNG-1 trial, the FDA has approved zongertinib for patients with HER2-mutated unresectable or metastatic non-squamous non-small cell lung cancer.
Based on results from the...
02/26/2026
Oncology

News

News
First-Line Zipalertinib Plus Chemotherapy Significantly Improves Progression-Free Survival in EGFR Exon 20-Mutated Non-Small Cell Lung Cancer
09/24/2026
Emily Estrada
Results from the phase 3 REZILIENT 3 trial showed that adding zipalertinib to platinum-pemetrexed chemotherapy significantly improved progression-free survival and response in patients with previously untreated EGFR exon 20 insertion-mutated...
Results from the phase 3 REZILIENT 3 trial showed that adding zipalertinib to platinum-pemetrexed chemotherapy significantly improved progression-free survival and response in patients with previously untreated EGFR exon 20 insertion-mutated...
Results from the phase 3...
09/24/2026
Oncology
News
Amivantamab Plus Chemotherapy Extends Median OS in Final PAPILLON Analysis of EGFR Exon 20-Mutant Non-Small Cell Lung Cancer
09/24/2026
Emily Estrada
Final results from the phase 3 PAPILLON trial showed numerically prolonged overall survival with first-line amivantamab plus chemotherapy in patients with EGFR exon 20 insertion-mutated non-small cell lung cancer, despite substantial...
Final results from the phase 3 PAPILLON trial showed numerically prolonged overall survival with first-line amivantamab plus chemotherapy in patients with EGFR exon 20 insertion-mutated non-small cell lung cancer, despite substantial...
Final results from the phase 3...
09/24/2026
Oncology
News
Chemotherapy-Free Durvalumab Plus Radiation Meets PFS End Point in Locally Advanced Non-Small Cell Lung Cancer
08/19/2026
Emily Estrada
Results from the phase 2 DART trial showed that concurrent and consolidative durvalumab plus definitive thoracic radiation met the prespecified 2-year progression-free survival benchmark in elderly and frail patients with locally advanced...
Results from the phase 2 DART trial showed that concurrent and consolidative durvalumab plus definitive thoracic radiation met the prespecified 2-year progression-free survival benchmark in elderly and frail patients with locally advanced...
Results from the phase 2 DART...
08/19/2026
Oncology
News
Ociperlimab Plus Tislelizumab Fails to Improve Survival Over Pembrolizumab in PD-L1-High Advanced Non-Small Cell Lung Cancer
08/11/2026
Emily Estrada
Ociperlimab plus tislelizumab failed to improve overall survival compared with pembrolizumab as first-line treatment for patients with stage III/IV non-small cell lung cancer and PD-L1 expression of ≥50%, leading to the phase 3 AdvanTIG-302...
Ociperlimab plus tislelizumab failed to improve overall survival compared with pembrolizumab as first-line treatment for patients with stage III/IV non-small cell lung cancer and PD-L1 expression of ≥50%, leading to the phase 3 AdvanTIG-302...
Ociperlimab plus tislelizumab...
08/11/2026
Oncology
News
Adjuvant Ensartinib Demonstrates Significant Disease-Free Survival Benefit in ALK-Positive Non-Small Cell Lung Cancer
07/09/2026
Stephanie Holland
Results from the phase 3 ELEVATE trial demonstrated that adjuvant ensartinib significantly improved disease-free survival compared with placebo in patients with completely resected ALK-positive non-small cell lung cancer, supporting its use...
Results from the phase 3 ELEVATE trial demonstrated that adjuvant ensartinib significantly improved disease-free survival compared with placebo in patients with completely resected ALK-positive non-small cell lung cancer, supporting its use...
Results from the phase 3 ELEVATE...
07/09/2026
Oncology
News
Osimertinib Plus Selumetinib Shows Limited Activity Following First-Line Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer
06/26/2026
Emily Estrada
Results from a phase 2 module of the ORCHARD study demonstrated that osimertinib plus selumetinib showed limited efficacy in patients with EGFR-mutated advanced non-small cell lung cancer harboring acquired BRAF alterations following disease...
Results from a phase 2 module of the ORCHARD study demonstrated that osimertinib plus selumetinib showed limited efficacy in patients with EGFR-mutated advanced non-small cell lung cancer harboring acquired BRAF alterations following disease...
Results from a phase 2 module of...
06/26/2026
Oncology
News
Benmelstobart Plus Anlotinib as Potential New First-Line Option in Advanced NSCLC
05/29/2026
Emily Estrada
Benmelstobart plus chemotherapy followed by maintenance benmelstobart and anlotinib significantly improved progression-free survival compared with a tislelizumab-based regimen in first-line EGFR/ALK/ROS1-wild type advanced non-squamous NSCLC.
Benmelstobart plus chemotherapy followed by maintenance benmelstobart and anlotinib significantly improved progression-free survival compared with a tislelizumab-based regimen in first-line EGFR/ALK/ROS1-wild type advanced non-squamous NSCLC.
Benmelstobart plus chemotherapy...
05/29/2026
Oncology
News
Sunvozertinib Significantly Improves PFS in EGFR-Mutated Non-Small Cell Lung Cancer
05/29/2026
Stephanie Holland
Results from the phase 3 WU-KONG28 trial demonstrated that sunvozertinib significantly improved PFS in previously untreated patients with advanced EGFR-mutated non-small cell lung cancer.
Results from the phase 3 WU-KONG28 trial demonstrated that sunvozertinib significantly improved PFS in previously untreated patients with advanced EGFR-mutated non-small cell lung cancer.
Results from the phase 3...
05/29/2026
Oncology
News
Lorlatinib Maintains Long-Term Benefit in Advanced ALK-Positive Non-Small Cell Lung Cancer
05/27/2026
Emily Estrada
Updated results from the phase 3 CROWN study demonstrate that lorlatinib sustains long-term benefit in treatment-naïve patients with advanced ALK-positive non-small cell lung cancer.
Updated results from the phase 3 CROWN study demonstrate that lorlatinib sustains long-term benefit in treatment-naïve patients with advanced ALK-positive non-small cell lung cancer.
Updated results from the phase 3...
05/27/2026
Oncology
News
Neoadjuvant Lorlatinib Produces Durable Early Outcomes in ALK-Positive NSCLC
05/27/2026
Emily Estrada
Results from a multicenter phase 2 study demonstrated that neoadjuvant lorlatinib induced high pathological response and enabled substantial conversion to surgery in advanced ALK-positive non-small cell lung cancer.
Results from a multicenter phase 2 study demonstrated that neoadjuvant lorlatinib induced high pathological response and enabled substantial conversion to surgery in advanced ALK-positive non-small cell lung cancer.
Results from a multicenter phase...
05/27/2026
Oncology

Interactive Features

Quiz
Lorlatinib for Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer
06/13/2024
True or False: Five-year long-term follow-up results from the phase 3 CROWN study demonstrated that first-line loraltinib improved outcomes among patients with advanced ALK-positive non-small cell lung cancer.
True or False: Five-year long-term follow-up results from the phase 3 CROWN study demonstrated that first-line loraltinib improved outcomes among patients with advanced ALK-positive non-small cell lung cancer.
True or False: Five-year...
06/13/2024
Oncology
Quiz
FDA Approves Alectinib for Patients With Resected ALK-Positive Non-Small Cell Lung Cancer
05/29/2024
According to results from the phase 3 ALINA trial the FDA has approved alectinib in the adjuvant setting for patients with resected ALK-positive non-small cell lung cancer. What is the recommended dose?
According to results from the phase 3 ALINA trial the FDA has approved alectinib in the adjuvant setting for patients with resected ALK-positive non-small cell lung cancer. What is the recommended dose?
According to results from the...
05/29/2024
Oncology
Quiz
Amivantamab Plus Chemotherapy for Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer
04/04/2024
According to results from the phase 3 PAPILLON trial, what percentage of patients remained on amivantamab plus chemotherapy at a follow-up of 18-months?
According to results from the phase 3 PAPILLON trial, what percentage of patients remained on amivantamab plus chemotherapy at a follow-up of 18-months?
According to results from the...
04/04/2024
Oncology
Quiz
FDA Approves Osimertinib Plus Chemotherapy For EGFR-Mutated Advanced NSCLC
03/21/2024
Based on results from the phase 3 FLAURA 2 trial the US FDA has approved osimertinib plus platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or exon...
Based on results from the phase 3 FLAURA 2 trial the US FDA has approved osimertinib plus platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or exon...
Based on results from the phase...
03/21/2024
Oncology
Quiz
Repotrectinib for ROS1 Fusion-Positive NSCLC
02/05/2024
02/05/2024
Oncology
Quiz
Sitravatinib Plus Nivolumab for Nonsquamous NSCLC After Progression on Checkpoint Inhibitors
05/16/2023
How did patients with nonsquamous non-small cell lung cancer who had progressed after checkpoint inhibitor immunotherapy respond to combination sitravatinib and nivolumab?
How did patients with nonsquamous non-small cell lung cancer who had progressed after checkpoint inhibitor immunotherapy respond to combination sitravatinib and nivolumab?
How did patients with...
05/16/2023
Oncology
Quiz
Pembrolizumab Plus Chemotherapy Efficacy by PD-L1 Status in Metastatic NSCLC
04/17/2023
Did PD-L1 tumor proportion score affect the improvement of long-term survival outcomes from pembrolizumab plus chemotherapy among patients with non-small cell lung cancer?
Did PD-L1 tumor proportion score affect the improvement of long-term survival outcomes from pembrolizumab plus chemotherapy among patients with non-small cell lung cancer?
Did PD-L1 tumor proportion score...
04/17/2023
Oncology
Quiz
Treatment-Related Adverse Events With Nivolumab Plus Ipilimumab for NSCLC
04/13/2023
Was combination nivolumab plus ipilimumab associated with a higher incidence of treatment-related adverse events than pembrolizumab monotherapy among patients with non-small cell lung cancer?
Was combination nivolumab plus ipilimumab associated with a higher incidence of treatment-related adverse events than pembrolizumab monotherapy among patients with non-small cell lung cancer?
Was combination nivolumab plus...
04/13/2023
Oncology
Quiz
First-Line Immune Checkpoint Inhibitor Monotherapy for NSCLC
02/15/2023
How did patients respond to first-line immune checkpoint inhibitor monotherapy compared to combination therapy for non-small cell lung cancer?
How did patients respond to first-line immune checkpoint inhibitor monotherapy compared to combination therapy for non-small cell lung cancer?
How did patients respond to...
02/15/2023
Oncology
Quiz
Quiz: Survival Outcomes With Pembrolizumab for Nonsquamous NSCLC
01/31/2023
Which survival outcomes did pemetrexed and platinum-based chemotherapy plus pembrolizumab improve in patients with nonsquamous non-small cell lung cancer?
Which survival outcomes did pemetrexed and platinum-based chemotherapy plus pembrolizumab improve in patients with nonsquamous non-small cell lung cancer?
Which survival outcomes did...
01/31/2023
Oncology

Recent News

News
First-Line Zipalertinib Plus Chemotherapy Significantly Improves Progression-Free Survival in EGFR Exon 20-Mutated Non-Small Cell Lung Cancer
09/24/2026
Emily Estrada
Results from the phase 3 REZILIENT 3 trial showed that adding zipalertinib to platinum-pemetrexed chemotherapy significantly improved progression-free survival and response in patients with previously untreated EGFR exon 20 insertion-mutated...
Results from the phase 3 REZILIENT 3 trial showed that adding zipalertinib to platinum-pemetrexed chemotherapy significantly improved progression-free survival and response in patients with previously untreated EGFR exon 20 insertion-mutated...
Results from the phase 3...
09/24/2026
Oncology
News
Amivantamab Plus Chemotherapy Extends Median OS in Final PAPILLON Analysis of EGFR Exon 20-Mutant Non-Small Cell Lung Cancer
09/24/2026
Emily Estrada
Final results from the phase 3 PAPILLON trial showed numerically prolonged overall survival with first-line amivantamab plus chemotherapy in patients with EGFR exon 20 insertion-mutated non-small cell lung cancer, despite substantial...
Final results from the phase 3 PAPILLON trial showed numerically prolonged overall survival with first-line amivantamab plus chemotherapy in patients with EGFR exon 20 insertion-mutated non-small cell lung cancer, despite substantial...
Final results from the phase 3...
09/24/2026
Oncology
News
Chemotherapy-Free Durvalumab Plus Radiation Meets PFS End Point in Locally Advanced Non-Small Cell Lung Cancer
08/19/2026
Emily Estrada
Results from the phase 2 DART trial showed that concurrent and consolidative durvalumab plus definitive thoracic radiation met the prespecified 2-year progression-free survival benchmark in elderly and frail patients with locally advanced...
Results from the phase 2 DART trial showed that concurrent and consolidative durvalumab plus definitive thoracic radiation met the prespecified 2-year progression-free survival benchmark in elderly and frail patients with locally advanced...
Results from the phase 2 DART...
08/19/2026
Oncology
News
Ociperlimab Plus Tislelizumab Fails to Improve Survival Over Pembrolizumab in PD-L1-High Advanced Non-Small Cell Lung Cancer
08/11/2026
Emily Estrada
Ociperlimab plus tislelizumab failed to improve overall survival compared with pembrolizumab as first-line treatment for patients with stage III/IV non-small cell lung cancer and PD-L1 expression of ≥50%, leading to the phase 3 AdvanTIG-302...
Ociperlimab plus tislelizumab failed to improve overall survival compared with pembrolizumab as first-line treatment for patients with stage III/IV non-small cell lung cancer and PD-L1 expression of ≥50%, leading to the phase 3 AdvanTIG-302...
Ociperlimab plus tislelizumab...
08/11/2026
Oncology
News
Adjuvant Ensartinib Demonstrates Significant Disease-Free Survival Benefit in ALK-Positive Non-Small Cell Lung Cancer
07/09/2026
Stephanie Holland
Results from the phase 3 ELEVATE trial demonstrated that adjuvant ensartinib significantly improved disease-free survival compared with placebo in patients with completely resected ALK-positive non-small cell lung cancer, supporting its use...
Results from the phase 3 ELEVATE trial demonstrated that adjuvant ensartinib significantly improved disease-free survival compared with placebo in patients with completely resected ALK-positive non-small cell lung cancer, supporting its use...
Results from the phase 3 ELEVATE...
07/09/2026
Oncology
News
Sunvozertinib Significantly Improves PFS in EGFR-Mutated Non-Small Cell Lung Cancer
05/29/2026
Stephanie Holland
Results from the phase 3 WU-KONG28 trial demonstrated that sunvozertinib significantly improved PFS in previously untreated patients with advanced EGFR-mutated non-small cell lung cancer.
Results from the phase 3 WU-KONG28 trial demonstrated that sunvozertinib significantly improved PFS in previously untreated patients with advanced EGFR-mutated non-small cell lung cancer.
Results from the phase 3...
05/29/2026
Oncology
News
Lorlatinib Maintains Long-Term Benefit in Advanced ALK-Positive Non-Small Cell Lung Cancer
05/27/2026
Emily Estrada
Updated results from the phase 3 CROWN study demonstrate that lorlatinib sustains long-term benefit in treatment-naïve patients with advanced ALK-positive non-small cell lung cancer.
Updated results from the phase 3 CROWN study demonstrate that lorlatinib sustains long-term benefit in treatment-naïve patients with advanced ALK-positive non-small cell lung cancer.
Updated results from the phase 3...
05/27/2026
Oncology
News
Neoadjuvant Lorlatinib Produces Durable Early Outcomes in ALK-Positive NSCLC
05/27/2026
Emily Estrada
Results from a multicenter phase 2 study demonstrated that neoadjuvant lorlatinib induced high pathological response and enabled substantial conversion to surgery in advanced ALK-positive non-small cell lung cancer.
Results from a multicenter phase 2 study demonstrated that neoadjuvant lorlatinib induced high pathological response and enabled substantial conversion to surgery in advanced ALK-positive non-small cell lung cancer.
Results from a multicenter phase...
05/27/2026
Oncology
FDA Approval
FDA Approves Zongertinib for HER2-Mutated Metastatic NSCLC
02/26/2026
Emily Estrada
Based on results from the Beamion LUNG-1 trial, the FDA has approved zongertinib for patients with HER2-mutated unresectable or metastatic non-squamous non-small cell lung cancer.
Based on results from the Beamion LUNG-1 trial, the FDA has approved zongertinib for patients with HER2-mutated unresectable or metastatic non-squamous non-small cell lung cancer.
Based on results from the...
02/26/2026
Oncology
News
Adjuvant Aumolertinib Improves Disease-Free Survival in Resected EGFR-Mutated Non–Small Cell Lung Cancer
01/21/2026
Stephanie Holland
Results from the phase 3 ARTS trial demonstrated that adjuvant aumolertinib significantly improved disease-free survival compared with placebo in patients with completely resected EGFR-mutated non-small cell lung cancer, supporting its use as...
Results from the phase 3 ARTS trial demonstrated that adjuvant aumolertinib significantly improved disease-free survival compared with placebo in patients with completely resected EGFR-mutated non-small cell lung cancer, supporting its use as...
Results from the phase 3 ARTS...
01/21/2026
Oncology
FDA Approval
FDA Approves Amivantamab and Hyaluronidase for Previously Treated Head and Neck Squamous Cell Carcinoma
11/06/2026
Stephanie Holland
Results from the phase 1b/2 OrigAMI-4 trial supported FDA accelerated approval of subcutaneous amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck squamous cell carcinoma, introducing a dual...
Results from the phase 1b/2 OrigAMI-4 trial supported FDA accelerated approval of subcutaneous amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck squamous cell carcinoma, introducing a dual...
Results from the phase 1b/2...
11/06/2026
Oncology
News
Varegacestat Advances Toward European Approval for Desmoid Tumors Following RINGSIDE Survival Benefit
11/05/2026
Emily Estrada
Based on results from the phase 3 RINGSIDE trial, the European Medicines Agency has validated the marketing authorization application for varegacestat in adults with desmoid tumors, following significant improvements in progression-free...
Based on results from the phase 3 RINGSIDE trial, the European Medicines Agency has validated the marketing authorization application for varegacestat in adults with desmoid tumors, following significant improvements in progression-free...
Based on results from the phase...
11/05/2026
Oncology
News
Lirafugratinib Receives NCCN Category 2A Recommendation Following FDA Approval in FGFR2-Altered Cholangiocarcinoma
11/05/2026
Emily Estrada
Following FDA approval supported by the phase 1/2 ReFocus trial, lirafugratinib has been added to the NCCN Guidelines as a Category 2A preferred subsequent-line treatment option for patients with cholangiocarcinoma harboring FGFR2 fusions or...
Following FDA approval supported by the phase 1/2 ReFocus trial, lirafugratinib has been added to the NCCN Guidelines as a Category 2A preferred subsequent-line treatment option for patients with cholangiocarcinoma harboring FGFR2 fusions or...
Following FDA approval supported...
11/05/2026
Oncology
News
Pumitamig Plus Chemotherapy Shows Antitumor Activity Regardless of Brain Metastasis Status
11/04/2026
Emily Estrada
Results from two phase 2 trials demonstrated encouraging intracranial responses with pumitamig plus chemotherapy in patients with small cell lung cancer and triple-negative breast cancer with brain metastases, supporting further investigation...
Results from two phase 2 trials demonstrated encouraging intracranial responses with pumitamig plus chemotherapy in patients with small cell lung cancer and triple-negative breast cancer with brain metastases, supporting further investigation...
Results from two phase 2 trials...
11/04/2026
Oncology
News
SEZ6-Targeted Antibody-Drug Conjugate ABBV-706 Demonstrates Promising Antitumor Activity in Relapsed or Refractory Small Cell Lung Cancer
11/04/2026
Emily Estrada
Updated phase 1 results demonstrated promising antitumor activity with the SEZ6-targeted antibody-drug conjugate ABBV-706 in relapsed or refractory small cell lung cancer, with encouraging response and survival outcomes alongside exploratory...
Updated phase 1 results demonstrated promising antitumor activity with the SEZ6-targeted antibody-drug conjugate ABBV-706 in relapsed or refractory small cell lung cancer, with encouraging response and survival outcomes alongside exploratory...
Updated phase 1 results...
11/04/2026
Oncology
News
Phase 1 Trial Shows 70% Response Rate With SKB500 in Heavily Pretreated Patients With Small Cell Lung Cancer
11/04/2026
Emily Estrada
Updated results from a phase 1 trial demonstrated promising antitumor activity with the B7-H3-directed antibody-drug conjugate SKB500 in heavily pretreated patients with small cell lung cancer, with the lower dose showing more favorable...
Updated results from a phase 1 trial demonstrated promising antitumor activity with the B7-H3-directed antibody-drug conjugate SKB500 in heavily pretreated patients with small cell lung cancer, with the lower dose showing more favorable...
Updated results from a phase 1...
11/04/2026
Oncology
News
Varegacestat Significantly Improves Pain, Physical Function, and Quality of Life in Patients With Desmoid Tumors
11/04/2026
Emily Estrada
Results from RINGSIDE trial demonstrated rapid and sustained improvements in patient-reported pain, desmoid-related symptoms, physical function, and quality of life with varegacestat compared with placebo in patients with progressing desmoid...
Results from RINGSIDE trial demonstrated rapid and sustained improvements in patient-reported pain, desmoid-related symptoms, physical function, and quality of life with varegacestat compared with placebo in patients with progressing desmoid...
Results from RINGSIDE trial...
11/04/2026
Oncology
FDA Alerts
Zanubrutinib Combination Receives FDA Priority Review Following Positive Phase 3 MANGROVE Results
11/04/2026
Stephanie Holland
Results from the phase 3 MANGROVE trial supported FDA Priority Review of zanubrutinib plus rituximab for previously untreated mantle cell lymphoma, following a significant progression-free survival benefit compared with bendamustine plus...
Results from the phase 3 MANGROVE trial supported FDA Priority Review of zanubrutinib plus rituximab for previously untreated mantle cell lymphoma, following a significant progression-free survival benefit compared with bendamustine plus...
Results from the phase 3...
11/04/2026
Oncology
News
Medicare Expands Coverage of Signatera MRD Testing for Hepatocellular Carcinoma Surveillance
11/03/2026
Stephanie Holland
Medicare coverage has been extended to serial Signatera molecular residual disease testing for surveillance of patients with early-stage hepatocellular carcinoma who have no evidence of disease following surgery, supported by real-world...
Medicare coverage has been extended to serial Signatera molecular residual disease testing for surveillance of patients with early-stage hepatocellular carcinoma who have no evidence of disease following surgery, supported by real-world...
Medicare coverage has been...
11/03/2026
Oncology
News
What to Expect at the 2026 NANETS Multidisciplinary NET Medical Symposium
11/02/2026
Janelle Bradley
The 2026 NANETS Multidisciplinary NET Medical Symposium will spotlight emerging research, evolving treatment strategies, and practical insights to advance neuroendocrine tumor care.
The 2026 NANETS Multidisciplinary NET Medical Symposium will spotlight emerging research, evolving treatment strategies, and practical insights to advance neuroendocrine tumor care.
The 2026 NANETS...
11/02/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use